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Abstract
Background: The lower incidence of breast cancer among Asian women compared with Western countries has been partly
attributed to soy in the Asian diet, leading to efforts to identify the bioactive components that are responsible. Soy Bowman
Birk Inhibitor Concentrate (BBIC) is a known cancer preventive agent now in human clinical trials.
Methodology/Principal Findings: The objectives of this work are to establish the presence and delineate the in vitro activity
of lunasin and BBI found in BBIC, and study their bioavailability after oral administration to mice and rats. We report that
lunasin and BBI are the two main bioactive ingredients of BBIC based on inhibition of foci formation, lunasin being more
efficacious than BBI on an equimolar basis. BBI and soy Kunitz Trypsin Inhibitor protect lunasin from in vitro digestion with
pancreatin. Oral administration of 3H-labeled lunasin with lunasin-enriched soy results in 30% of the peptide reaching target
tissues in an intact and bioactive form. In a xenograft model of nude mice transplanted with human breast cancer MDA-MB-
231 cells, intraperitoneal injections of lunasin, at 20 mg/kg and 4 mg/kg body weight, decrease tumor incidence by 49%
and 33%, respectively, compared with the vehicle-treated group. In contrast, injection with BBI at 20 mg/kg body weight
shows no effect on tumor incidence. Tumor generation is significantly reduced with the two doses of lunasin, while BBI is
ineffective. Lunasin inhibits cell proliferation and induces cell death in the breast tumor sections.
Conclusions/Significance: We conclude that lunasin is actually the bioactive cancer preventive agent in BBIC, and BBI
simply protects lunasin from digestion when soybean and other seed foods are eaten by humans.
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Introduction
Breast cancer is the most common malignant tumor among
women and the leading causes of death of women in Western
countries [1]. In contrast, breast cancer incidence in most Asian
countries is approximately 10% that of the general population of the
USA and Europe [2]. Of all environmental factors known to
influence breast cancer, diet appears to be one of the most significant.
Asian diets are rich in soybean products containing factors that have
been found to provide important protection against initiation,
promotion and/or progression of breast cancer in animal models
[3]. In 1980, Troll and coworkers suggested the possibility that soy
protein might have a role in preventing breast cancer in irradiated
rats [4]. Animal experiments carried out during the last decade have
confirmed the breast cancer preventive role of soy protein [2,3]. In
particular, bioactive peptides isolated from soybeans, such as lunasin
and the Bowman-Birk protease inhibitor (BBI) are now being
intensively studied as cancer chemopreventive agents.
Lunasin is a novel peptide initially identified in soybean [5] and
subsequently, isolated in wheat, barley and other seeds [6–9]. It is
a 43-amino acid peptide which efficacy has been demonstrated in
mammalian cells against chemical carcinogens and viral onco-
genes [10,11]. The first mouse model confirmed the chemopre-
ventive activity of lunasin against skin cancer induced by a
chemical carcinogen [10]. These results suggest that lunasin may
exert a promising role as preventive agent against other types of
cancer, such as breast cancer.
BBI is a polypeptide of 71 amino acids with the ability to inhibit
the serine proteases trypsin and chymotrypsin. The trypsin
inhibitory site of BBI has been associated with negative effects
on bioavailability of dietary proteins, whereas the chymotrypsin
site has been implicated in cancer chemopreventive effects [12,13].
The high cost of BBI’s purification process has made necessary
the use of an impure form of BBI called BBI concentrate (BBIC)
that has been reported to exert chemopreventive activity against
different types of cancer induced by chemical carcinogens and
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radiations [14]. These studies consider that BBI is the main
component responsible for BBIC’s chemopreventive activity,
without evaluating the contribution of other peptides contained
in the BBIC on its cancer preventive activity.
Oral administration has been recognized as a plausible and cost-
effective approach to reduce cancer morbidity and mortality by
inhibiting precancerous events before the occurrence of clinical
disease [15]. Since lunasin and BBI are peptides, it is crucial to
establish whether they, once orally ingested, survive digestion and
get absorbed, reaching the target tissues and organs in an intact
and bioactive state. Park and coworkers carried out in vitro studies
demonstrating the role of BBI in protecting lunasin from digestion
when soy protein was orally consumed [16]. However, there are
no in vivo studies examining the role of BBI in protecting lunasin
from digestion in the gastrointestinal tract of animals.
The aims of this work are to evaluate the presence and in vitro
activity of lunasin and BBI contained in BBIC and study their
bioavailability after oral administration to mice and rats. A xeno-
graft breast cancer mouse model was chosen to delineate and
evaluate in vivo the chemopreventive properties of lunasin and BBI
separately and to elucidate the carcinogenesis pathways involved
in breast cancer that are affected by these peptides.
Results
Lunasin Is a Bioactive Ingredient of BBIC
To determine the composition of BBIC, this preparation was
subjected to SDS-PAGE and Western-Blot to identify lunasin and
BBI. The results show that both peptides are present in BBIC at
concentrations of 360 and 74.4 ng/mg protein, respectively
(Figure 1A). The two represent about 44% of total protein of
the BBIC, indicating that other proteins are present and may
contribute to the properties attributed to this preparation.
Foci formation inhibitory activity of BBIC containing 1160 nM
BBI and 100 nM lunasin was analyzed. BBIC suppressed foci
formation by 80% in 7,12-dimethylbenz[a]anthracene (DMBA)-
induced NIH3T3 cells, compared to vehicle-treated cells
(Figure 1B–C). Lunasin and BBI were individually purified from
the BBIC and their activities analyzed. 100 nM of pure lunasin
isolated from BBIC reduced foci formation by 73% (Figure 1B–E),
which is identical to that observed with 100 nM synthetic lunasin
(Figure 1B–G). Pure BBI isolated from the BBIC at concentration
of 100 nM decreases foci formation by 60% (Figure 1B–D). Thus,
lunasin was more effective than BBI by 18% on an equimolar
basis, but BBI also has a chemopreventive effect of its own, most
likely due to inhibition of proteolytic processes involved in
carcinogenesis.
Soy Protease Inhibitors Protect Lunasin from In Vitro
Digestion
In order to establish the role of the different protease inhibitors
contained in soybean, such as BBI and Kunitz Trypsin Inhibitor
(KTI), synthetic lunasin was subjected to an in vitro digestion
process with pancreatin. Lunasin was incubated with this pre-
paration in the absence and presence of BBI and KTI and
evaluated by Western-Blot. The pattern shows (Figure 2) that both
protease inhibitors protect lunasin from digestion, even after being
denatured by heat treatment. Approximately 93% and 97% of
lunasin remain intact after the digestion process in the presence of
unboiled BBI and KTI, respectively. Similar percentages of
lunasin (98% and 84%) remained intact when this peptide was
incubated with pancreatin in the presence of boiled BBI and KTI,
respectively. Lunasin resists heat treatment [17], and is present in
different processed soybean products that also contain BBI [18].
All these results indicate that lunasin would be bioavailable after
ingestion of these products due to the protective role of BBI and
other soy protease inhibitors.
Lunasin Is Bioavailable When Orally Administered to Mice
and Rats
Mice and rats were used to determine whether orally ingested
lunasin survives digestion, ends up in the tissues and remains intact
and bioactive as measured by an in vivo assay. In the first set of
experiments, CD-1 mice received 3H-labelled synthetic lunasin
mixed with lunasin-enriched soy (LES) by gavage. Lunasin is
absorbed and distributed in various collected tissues, including
those that are targets for the most common cancers, such as lung,
mammary gland and prostate (Figure 3A). It is noteworthy that
lunasin is able to cross the blood-brain barrier, reaching the brain.
At 3 hrs post-gavage, approximately 30% of the total oral dose of
lunasin is absorbed (Figure S1).
Since the 3H-radioactivity would not show the molecular size
and bioactivity of lunasin in the tissues, rats were fed dietary LES
for 4 weeks, the blood and liver were collected and lunasin was
extracted, purified, and analyzed by Western-blot. Lunasin is
present in the blood of LES-fed rats as a monomer at a
concentration of 17.5 ng/ml. However, lunasin isolated from the
liver of LES-fed rats exists as a dimer at a concentration of
3.1 mg/g of liver (Figure S2). Lunasin (1 mM) extracted from the
liver of LES-fed rats suppresses foci formation as effectively as an
Figure 1. Lunasin is the main bioactive component in BBIC. A:
Western-Blot of BBIC using antibodies specific for BBI and lunasin. (1)
Marker, (2) 6.25 mg protein, (3) 12 mg protein, (4) 25 mg protein, (5) Standard
BBI (3 mg) or standard lunasin (200 ng). B: Foci formation inhibitory activity
in DMBA-induced NIH3T3 cells. (a) Vehicle-treated cells (b) positive control
or DMBA-treated cells, (c) BBIC (100 nM lunasin +1160 nM BBI), (d) BBI
(100 nM) from BBIC, (e) Lunasin (100 nM) from BBIC, (f) Standard BBI
(100 nM), (g) Synthetic lunasin (100 nM). Bars with different lower case
letter designations are statistically significantly different from each other
(P,0.05, n=6).
doi:10.1371/journal.pone.0008890.g001
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equimolar amount of synthetic lunasin (Figure 3B). In contrast, the
control protein band extracted from LES-unfed rats is ineffective
in suppressing foci formation.
Lunasin Reduces Tumor Incidence and Generation
To examine the in vivo effect of lunasin and BBI in breast cancer
cells, MDA-MB-231 cells were implanted subcutaneously into
nude mice after 2 months intraperitoneal (i.p.) injection of lunasin
and BBI. No significant differences in body weights were observed
among the four groups (Figure 4A), suggesting that lunasin or BBI
treatments has no side effects on the general health condition.
These results are consistent with studies carried out by Johnson
and coworkers [19] who reported no significant effects on body
weight after daily gavage of BBIC (500,2000 mg/kg/day) for six
months.
Breast cancer incidence of mice is shown in Figure 4B. At seven
weeks post-cells injection, 75% and 88% of mice in control and
BBI-groups, respectively showed tumors. In contrast, tumor
incidence was 38% and 50% in mice treated with 20 mg/kg
and 4 mg/kg lunasin, respectively. Thus, compared with the
control, the tumor incidence was 49% and 33% lower in the
lunasin-treated groups respectively. Compared with the BBI
group, the tumor incidence was 57% lower in the 20 mg/kg
and 43% lower in the 4 mg/kg lunasin treated group. Mice
treated with lunasin also showed a delay in the appearance of
tumors. Moreover, tumor generation, was reduced in the two
groups of mice treated with lunasin, being significantly lower in
mice treated with the lowest dose of lunasin, 70% and 69% lower
relative to control and BBI group respectively (P= 0.029 vs
control) (Figure 4C).
Growth rate and final size of the tumors differed among the four
groups. Significant tumors appeared in control mice after cells
injection whereas the sizes of tumors in mice treated with 20 mg/
kg and 4 mg/kg lunasin were decreased by 23% and 34%,
respectively (Figure 5A). At the end of the experiment, the weight
of tumors was also lower in mice treated with both doses of lunasin
compared to control-group (P= 0.2134, 0.1880, respectively) and
BBI-group (P= 0.0909, 0.0569, respectively) (Figure 5B).
Palpable and non-palpable mammary tumors were collected
and subjected to histological analysis and immunostaining. After
H&E staining (Figure 6A), tumor sections of lunasin-treated
groups showed tumor destruction areas replaced by apoptotic and
necrotic cells that were not apparent in the control and BBI-
treated groups. To establish greater specificity for the antiprolif-
erative response, tumor sections were analyzed by immunohisto-
chemistry for Ki-67 expression, an indicator of cell proliferation
[20]. Lunasin treatment at 20 mg/kg and 4 mg/kg reduced Ki-67
expression by 34% (P= 0.0062) and 30% (P= 0.0158), respective-
ly, compared with the control group (Figure 6B). However, there
was no significant difference between the Ki-67 expression of
control and BBI-groups. In situ TUNEL assay was performed to
evaluate the apoptotic effect of lunasin and BBI treatments
(Figure 6C). TUNEL-positive apoptotic cells were found in tumors
from animals treated with both doses of lunasin, revealing a
significantly increased apoptosis in these treatment groups
compared to the control group (P= 0.0088, 0.0141, respectively).
Few TUNEL-positive cells were found in tumors from animals in
the BBI-group. These suggest that tumors from mice treated with
lunasin have significantly lower rate of proliferation and higher
apoptosis index compared to control and BBI groups.
Discussion
The high prevalence of breast cancer has provided a strong
rationale for identifying new compounds for use as preventive
and/or therapeutic agents. Epidemiological studies, animal ex-
periments and human trials have shown evidence that people
consuming a soy-rich diet have lower incidence and mortality
from breast cancer, leading to investigations on different
compounds from soy that provide protection against breast
cancer [21,22]. Daily intake of these anticancer compounds could
be compared to a preventive, non-toxic version of chemotherapy
that is harmless to the physiology of normal tissue and stops
microtumours [23,24]. To evaluate the potential risks and
benefits of phytochemicals to human health, understanding of
the physiological behavior of these compounds following oral
ingestion as well as of their absorption, distribution, metabolism,
and excretion is needed [15].
The soybean BBIC is largely a preparation containing the
protease inhibitor BBI that has been used to demonstrate the
chemopreventive properties of this peptide avoiding the high cost
of its purification. Several studies have reported the chemopre-
ventive role of the BBIC against different types of cancer induced
by chemical carcinogens and radiations [14,25]. These studies
have assumed that BBI is the main bioactive compound
responsible for BBIC’s chemopreventive activity, without evaluat-
ing the contribution of other minor peptides. Our results show that
BBIC contains both lunasin and BBI representing 44% of total
protein. The in vitro foci formation inhibitory activity assay shows
that lunasin exerts 18% higher activity in DMBA-induced
NIH3T3 cells than BBI on an equimolar basis. However, it
is clear that the protease inhibitory activities of BBI and KTI
Figure 2. Soy-derived BBI and KTI protect synthetic lunasin
from in vitro digestion. The upper, lighter bands are Coomassie Blue
protein stains and the lower, darker bands are Western blots. (M)
Markers, (1) Lunasin (600 ng) + pancreatin (600 ng) incubated for 0 h at
37uC, (2) Lunasin (600 ng) + pancreatin (600 ng) incubated for 1 h at
37uC, (3) Lunasin (600 ng) + BBI (18,000 ng, unboiled) + pancreatin
(600 ng) incubated for 1 h at 37uC, (4). Lunasin (600 ng) + KTI
(18,000 ng, unboiled) + pancreatin (600 ng) incubated for 1 h at
37uC, (5) Lunasin (600 ng) + BBI (18,000 ng, boiled) + pancreatin
(600 ng) incubated for 1 h at 37uC, (6) Lunasin (600 ng)+KTI (18,000 ng,
boiled) + pancreatin (600 ng) incubated for 1 h at 37uC, (7) BBI
(unboiled), (8) KTI (unboiled).
doi:10.1371/journal.pone.0008890.g002
BBIC’s Role in Cancer
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8890
are essential in protecting lunasin from in vitro digestion with
pancreatin. In vivo experiments, carried out with mice and rats fed
LES, have demonstrated that lunasin, orally ingested, resists
digestion, gets absorbed and reaches the target tissues and organs
in an intact and bioactive state. Recently, it has been
demonstrated that lunasin is bioavailable in humans fed soy
protein products, an important requirement for its anticancer
potential [26]. Thus, the protective roles of BBI and KTI and
perhaps other naturally occurring protease play a major role in
making lunasin available in soy protein to exert its chemopreven-
tive properties. Bioavailability after oral administration of a
chemopreventive agent is crucial to understanding the various in
vivo mechanisms responsible for its cancer preventive activity [27].
In order to delineate the individual in vivo preventive properties
against breast cancer of lunasin and BBI, each peptide was
injected separately into nude mice before and after injection of
MDA-MB-231 cells. In our study, one dose of BBI and two doses
of lunasin were assessed. The low dose (4 mg/kg body weight) of
lunasin corresponds to the daily intake of soy protein considered
by FDA to reduce cardiovascular disease, and also in accordance
to the results of our present study showing that 30% of ingested
lunasin reaches the target tissues. The use of the higher dose
(20 mg/kg body weight) is based on the finding that i.p.
administration of BBI at this dose significantly suppresses effect
on 3-methylcholanthrene-induced lung tumors in A/J mice [28].
Both doses of these peptides appear to be well tolerated by the
mice as evidenced by lack of change in body weight during the
15-week treatment period. Mice treated with lunasin show
reduction in breast tumor incidence and delay in the appearance
of tumors. Tumor generation is also significantly inhibited at the
lower dose of lunasin. Moreover, the volume and weight of tumors
generated in lunasin-treated groups are lower compared with
control and BBI-groups. No effects on breast tumor development
are observed when BBI was used in MDA-MB-231 xenograft
mice.
In order to better understand the specific mechanisms by
which lunasin exerts its effects on MDA-MB-231 breast tumors,
biomarkers of cell proliferation and apoptosis which are good
indicators of tumor size in xenograft model were evaluated
[29,30]. Histological staining of sections obtained from lunasin-
treated tumors shows that tumor destruction areas are replaced by
apoptotic and necrotic cells. Lunasin treatment also results in a
significant reduction of cell proliferation and induction of
apoptosis in the MDA-MB-231 tumors. These effects are not
observed in tumors from BBI-treated mice.
Chemopreventive properties of lunasin have been demonstrated
in vivo in previous studies. In the first animal model, lunasin applied
topically at 250 mg/week suppresses skin papilloma formation in
SENCAR mice treated with DMBA and tetradecanoylphorbol-13-
acetate by 70% compared with the control. Tumor multiplicity is
also reduced and the appearance is delayed by 2 weeks in mice
treated with lunasin relative to the control [10]. This is consistent
with another observation that lunasin slows down epidermal cell
proliferation in mouse skin in the absence and presence of DMBA
Figure 3. Lunasin is absorbed through gastrointestinal barrier and reach the target tissues and organs in an intact and bioactive
state. A: Distribution of 3H-lunasin activity in various tissues and gastrointestinal contents of mice after ( ) 3 h, ( ) 6 h, ( ) 9 h, ( ) 12 h and ( )
24 h of oral administration of LES. Error bars shown for 3 h-results. B: Foci formation inhibitory activity in DMBA-induced NIH3T3 cells. (a) Vehicle-
treated cells, (b) DMBA-treated cells, (c) synthetic lunasin, (d) lunasin extracted from liver of rats fed control diet, (e) lunasin extracted from liver of rats
fed LES diet. Bars with different lower case letter designations are statistically significantly different from each other (P,0.05, n = 6).
doi:10.1371/journal.pone.0008890.g003
BBIC’s Role in Cancer
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using a 2H2O labeling method to measure cell proliferation in vivo
[31]. All these support our findings that lunasin acts as a cancer
preventive agent in vivo.
Kennedy has demonstrated that BBI has significant cancer
chemopreventive activity in both in vitro and in vivo bioassay
systems [25]. Although BBI has a broad spectrum of cancer-
protective activities, its effects on breast cancer remains limited.
BBI has been previously analyzed for its bioactivity against other
types of cancer, such as oral mucosa, colon, and lung cancer
[28,32,33]. However, no in vivo studies reporting the effect of BBI
as breast cancer preventive peptide have been published.
Nevertheless, there are some in vitro studies showing that BBI
decreased estrogen dependent human breast cancer cell growth
[34–36]. Wan and coworkers [37] demonstrated the growth
inhibitory properties of BBI in human prostate cancer xenografts
in nude mice. Our results using the xenograft model where lunasin
and BBI were evaluated separately show that BBI exhibits very
little chemopreventive effect against breast cancer. More studies
are needed to determine if tumor cell type and its specific
carcinogenesis pathways may be determinants of the cancer
chemopreventive properties of BBI.
In summary, our findings show that lunasin and BBI are the two
main bioactive ingredients of BBIC. In foci formation assay,
lunasin is about 18% more effective than BBI. However, the in vivo
xenograft model shows that while lunasin exhibit substantial
chemopreventive and therapeutic effects, BBI shows very little. We
propose that to explain the observed chemopreventive properties
of soy and other seeds containing lunasin, naturally occurring
protease inhibitors such as BBI and KTI, mainly protect lunasin
from digestion, making it bioavailable. This theme of comple-
mentarity of naturally occurring molecules in bringing about
health benefits to humans is likely quite common in nature and
speaks for eating whole foods rather than isolated components.
Materials and Methods
Purification of Lunasin and BBI from BBIC
To prepare the BBIC, 50 g finely-ground soybeans were
extracted with 1250 ml of hexane at 4uC for 24 hrs and then re-
extracted with 1250 ml of 60% ethanol at 55,60uC for 1 h. After
extraction, pH of the solution was adjusted to 5.3, and the BBIC
was precipitated with 2500 ml of acetone for 15 min. The
precipitate was dissolved in 100 ml of distilled water, dialyzed at
4uC for 24 hrs, and freeze-dried.
Separation of lunasin and BBI from the BBIC was carried out
by ion exchange chromatography. The column (AG MP-1M,
Figure 4. Lunasin reduces breast tumor development in MDA-MB-231 tumor xenografts in athymic nude mice. A: Body weight of mice
treated with (¤) PBS (control), (%) 20 mg BBI/kg body weight, (m) 20 mg lunasin/kg body weight, and (6) 4 mg lunasin/kg body weight, and
injected with 16107 MDA-MB-231 cells in the flank of 15-week-old nude mice. No significant differences were observed among four groups. B: Tumor
incidence in mice treated with PBS, BBI and two doses of lunasin. Lunasin reduced number of mice that showed tumors and delayed the appearance
of these breast tumors. C: Tumor generation in mice treated with PBS, BBI and two doses of lunasin. Low dose of lunasin (4 mg/kg body weight)
significantly reduced tumor generation compared to control group (*P= 0.029). Data are shown: mean 6 SEM (n = 8).
doi:10.1371/journal.pone.0008890.g004
BBIC’s Role in Cancer
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5.0650 cm, Bio-Rad Laboratories, Hercules, CA, USA) was
equilibrated with 0.1 M sodium phosphate buffer saline (PBS,
pH 7.0). Five hundred mg of BBIC dissolved in 0.1 M PBS were
applied into the column and chromatographic separations were
carried out with various concentration of NaCl in PBS at 4uC at a
flow rate of 30 ml/h. The different collected fractions were
subjected to Western-Blot for detection of lunasin and BBI as
described previously [8]. Briefly, SDS-PAGE was carried out using
16.5% tris-tricine gels (Bio-Rad). The proteins were transblotted
onto nitrocellulose membrane and blocked in 5% nonfat dry
milk dissolved in Tris-buffered saline 1% Tween 20 (TBS-1T).
The membrane was washed with TBS-1T and incubated with
lunasin polyclonal antibody (Zymed, Inc., South San Francisco,
CA, USA), or monoclonal BBI antibody, kindly provided by Dr.
David Brandon (USDA, WRRL, Albany, CA, USA). After
washing, the membrane was incubated for 1 h with horseradish
peroxidase conjugated secondary antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). The membrane was detected
using the detection agent (Amersham Biosciences, Piscataway, NJ,
USA) and immediately developed using 667 Polaroid films.
The intensities of the bands were quantified using the software
Un-SCAN-IT gel version 5.1 (Silk Scientific, Inc. Orem, UT, USA).
Lunasin and BBI contents were calculated by comparing the band
intensities with those of known standards lunasin and BBI run
under the same conditions.
Foci Formation Assay
The foci formation assay was performed according to Reznik-
off et al [38]. NIH3T3 cells were obtained from American
Type Culture Collection (ATCC) and cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS)
(Invitrogen, Carlsbad, CA, USA). Cells were plated at a density
of 500 cells/well in 12-well plates, incubated overnight at 37uC
and treated with lunasin or BBI for 4 hrs. Then, cells were
treated with 1.5 mg/ml DMBA for 20 hrs. After washing with
PBS, fresh medium was added. Peptides were added and medium
Figure 5. Effects of BBI and lunasin on the growth of MDA-MB-231 tumors in athymic nude mice. A: Tumor volume (mm3) of breast
tumors induced by the administration of (¤) PBS (control), (%) 20 mg BBI/kg body weight, (m) 20 mg lunasin/kg body weight and (6) 4 mg/kg of
lunasin. B: Breast tumors weight induced by PBS (control), 20 mg BBI/kg body weight, 20 mg lunasin/kg body weight (P=0.2134 vs control group
and 0.0909 vs BBI group) and 4 mg lunasin/kg body weight (P=0.1880 vs control group and 0.0569 vs BBI-group). Data are shown mean 6 SEM
(n = 8).
doi:10.1371/journal.pone.0008890.g005
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was changed every week for 6 weeks. At the end of experiment,
cells were washed with 0.9% NaCl, fixed with methanol, stained
with Giemsa, and scored for transformed foci. The negative
control was a set of cells receiving no DMBA, while the positive
control consisted of cells induced by DMBA but without
treatment.
In Vitro and In Vivo Bioavailability Studies
In vitro digestion of lunasin was carried out following the
method published in the United States Pharmacopeia [39].
Synthetic lunasin (American Peptide Company, Inc. Sunnyvale,
CA, USA) (5 mg) was incubated with the protease inhibitors
BBI or KTI (Sigma, St. Louis, MO, USA) for 30 min at 25uC.
Pancreatin from porcine pancreas (Sigma) was added (enzyme:-
protein ratio of 1:10) and solution was incubated at 37uC
for 1 h. Tris-tricine sample buffer was added at the end of
the reaction and immediately stopped by placing the tubes
in a boiling water bath for 5 min. The digests were analyzed by
SDS-PAGE and Western-Blot following the protocol previously
described.
Bioavailability studies in mice were done at North View Pacific
Laboratories (Hercules, CA, USA), according with the Animal
Care and Use Committee (ACUC) human guidelines. CD-1 mice
(3-5 weeks old) were purchased from Jackson Laboratories (Bar
Harbor, ME, USA) and conditioned on AIN76A diet for one
week. Forty mice (20 male and 20 female) were fasted for 8 hrs
before oral administration by gavage. Mice were separated into
two groups, a control group receiving 240 mg of LES formulation
and a treatment group receiving 240 mg of LES formulation plus
8 mCi of 3H-lunasin (SibTech, Inc. Brookfield, CT, USA) in
0.1 mL of 10% sucrose solution. Four mice of each group were
sacrificed at 3, 6, 9, 12 and 24 hrs after oral administration.
The tissue samples were collected and prepared for scintillation
counting by solubilizing in TS-2 tissue solubilizer (Research
Products International Corp., Chicago, IL, USA) and addition of
15% benzoyl peroxide. Each sample was read in 5 ml of
HionicFluor cocktail mix using a 1600TR liquid scintillation
counter (Packard Inst. Meriden CT, USA).
Sprague-Dawley Rats (Female, 5-weeks old) were purchased
from Central Laboratory Animal Inc. (Korea), and experiments
Figure 6. Histological features of MDA-MB-231 tumors treated with PBS (control), BBI and lunasin in athymic nude mice (4006
magnification). A: Tumors were collected at 7 week after breast cancer cells injection, and processed for H&E staining. Representative pictures are
shown for H&E-stained sections (upper column), immunohistochemical staining for Ki-67 (middle column) and in situ TUNEL apoptotic indices
(bottom column). B: Percentage of Ki-67 expression in tumors of mice. Ki-67 labeling revealed significantly lower levels of proliferating cells in lunasin
groups versus control group (*P=0.0062 in high lunasin group; *P=0.0158 in low lunasin group). C: Percentage of apoptotic cells in tumors of mice
measured with the TUNEL assay. Staining revealed significantly higher levels of apoptotic tumor cells in lunasin groups versus control group.
(*P= 0.0088 in high lunasin group; 0.0141 in low lunasin group). Data are shown mean 6 SEM.
doi:10.1371/journal.pone.0008890.g006
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were done according with guidelines of the Animal Center at
Andong National University (Andong, Korea). Five rats were fed
ad libitum with LES and potato starch (0.25% of the diet) for 4
weeks, and then sacrificed. Livers and serum were collected and
freeze-dried immediately. One gram of the freeze-dried tissues was
extracted with 0.1 M PBS (pH 7.0) (buffer:tissue ratio (v/w) = 1:3)
at 4uC for 24 hrs, and then centrifuged at 15000 rpm for 1 h. The
supernatant protein was further purified by ion exchange
chromatography on Biogel resin AG 1-X4 (BioRad), as described
by Jeong et al. [40]. Lunasin was further purified by injecting 20 ml
of filtrate into the HPLC system equipped with a C18 column
(Proteo 90A, Phenomenex Co., Torrance, CA, USA) equilibrated
at ambient temperature and an UV detector (295 nm) stabilized
with the mobile phase (acetonitrile:water = 4:6), at a flow rate of
2.5 ml/min for 15 min. Lunasin was identified by comparison
with the retention time of standard synthetic lunasin peak. The
lunasin fraction was collected, freeze dried and analyzed by SDS-
PAGE and Western-Blot as described above.
Breast Cancer Prevention in a Xenograft Mouse Model
Human MDA-MB-231 breast cancer cells were obtained from
ATCC and grown in Leibovitz’s L-15 Medium supplemented with
10% FBS, 100 unit/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen), in a humidified atmosphere at 37uC.
Mice protocol was approved by ACUC (University of
California, Berkeley, CA, USA). Thirty-two six weeks-old athymic
NCr-nu/nu mice (National Cancer Institute, Frederick, MD,
USA) were acclimatized for 1 week and randomly divided into
four groups (n = 8): control group (receiving PBS), BBI-group
(receiving BBI at 20 mg/kg body weight), and two lunasin-groups
(receiving synthetic lunasin [Chengdu KaiJie Bio-Pharmaceutical
Co., Chengdu, P.R. China] at 20 mg/kg body weight and
4 mg/kg body weight). After two months of i.p. treatment three
times a week, mice were injected subcutaneously in the right flank
with 16107 MDA-MB-231 cells suspended in 0.1 ml of Matrigel
Basement Membrane Matrix (Becton Dickinson, Bedford, MA,
USA). Tumor growth was monitored by palpation, and the onset
when tumors were detectable was noted. Tumor size was
measured with calipers, and tumor volume was calculated
assuming the shape as ellipsoid. Tumor incidence in percentage
was calculated as the number of tumor-bearing mice divided by
the total number of mice in each group, whereas tumor generation
was calculated as the total number of tumors divided by total
number of mice in each group [10]. The volume of the tumor was
determined using the following formula: tumor volume = length6
width260.523 [41].
Histological Analysis
At the end of the experiment, animals were sacrificed, and
tumors were dissected and weighed. Individual tumors were split
for fixation in the Shando Glyo-FixxTM (Thermo Scientific,
Pittsburgh, PA, USA) for histological examination. The paraffin-
embedded sections were stained with hematoxylin and eosin
(H&E).
Immunohistochemical Staining for Ki-67 Labeling Index
Sections were evaluated for tumor cell cytology, growth pattern,
necrosis and apoptosis. The 5 mm sections were deparaffinized and
rehydrated and antigens were retrieved using citrate buffer (pH 6.0)
before endogenous peroxidase activity was blocked. Proliferation
was shown using an antibody against Ki-67 (MIB-1; DakoCytoma-
tion, Glostrup, Denmark, dilution 1:75). Antigen expression was
expressed using streptavidin conjugated to horseradish peroxidase
and visualized by diaminobenzidine chromogen reagent (DakoCy-
tomation). All immunohistochemistry slides were examined by
light microscopy (Axiophot 381, Zeiss, Germany). Ki-67 labeling
index was calculated as percentage of positive cells over total
number of cells counted in microscope at 4006magnification [30].
In Situ TUNEL Assay for Apoptosis
In situ terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay was performed using ApopTag
Detection Kit (Millipore, USA & Canada) and ran based on the
manufacturer’s protocol. Briefly, deparaffinized and rehydrated
sections were pretreated with 20 mg/mL proteinase K for 15 min
and incubated with terminal transferase and digoxigenin dUTP at
37uC for 1 h. After washing, sections were incubated with
antidigoxigenin rhodamine (Millipore) and DAPI (Invitrogen),
and slides were visualized by fluorescent microscopy (Axiophot
381). The apoptotic cells were calculated as percentage of positive
cells over total number of cells counted in microscope at 4006
magnification.
Statistical Analysis
All data were analyzed from three independent experiments.
Results were expressed as the mean 6 standard deviation. The
Duncan test and one-way analysis of variance (ANOVA) were
used for multiple comparisons (SPSS software, version 12.0) of
data obtained by in vitro experiments. Comparison of results
obtained from animal experiments was performed using Student’s
t-test. A P-value less than 0.05 was considered statistically
significant.
Supporting Information
Figure S1 Recovery of 3H-lunasin dose (expressed in percent-
age) in (-m-) total, (-N-) tissues, and (-o-) gastrointestinal contents
of mice at 3, 6, 9, 12, and 24 hours post-gavage of lunasin-
enriched soy (LES). CD-1 mice received 240 mg of LES
formulation plus 8 mCi of 3H-lunasin (SibTech) in 0.1 ml of
10% sucrose solution. Before gavage, the mice were fasted for
8 hours and then sacrificed at 3, 6, 9, 12, and 24 hrs after oral
administration.
Found at: doi:10.1371/journal.pone.0008890.s001 (0.39 MB TIF)
Figure S2 Lunasin was extracted from blood and liver of rats fed
control and lunasin-enriched soy (LES) diets for four weeks. Upper
panels of the figure (A and C) correspond to gels stained with
Coomassie Blue of blood and liver, respectively. Lower panels (B
and D) correspond to Western blot analysis of blood and liver,
respectively. 1: MW marker; 2: Blood and 29 liver from rats fed
control diet; 3: Blood and 39 liver from rats fed control diet and
purified by anion exchange-HPLC; 4: Blood and 49 liver from
LES-fed rats; 5: Blood and 59 liver from LES-fed rats and purified
by anion exchange-HPLC; L: Synthetic lunasin 165 nM. Lunasin
contained in the blood of LES-fed rat was only detectable after
purification process.
Found at: doi:10.1371/journal.pone.0008890.s002 (2.09 MB TIF)
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